DFTX

Definium Therapeutics, Inc. Common Shares

37.65

USD

-2.67

-6.62%

Sep 23, 16:00 UTC -4

Closed

After-Market

37.87

+0.22

+0.58%

DFTX Earnings Reports

Positive Surprise Ratio

DFTX beat 0 of 4 last estimates.

Next Report

Date of Next Report

Nov 04, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.56

Implied change from Q2 26 (Revenue/ EPS)

-61.11%

Implied change from Q3 25 (Revenue/ EPS)

-28.21%

Definium Therapeutics, Inc. Common Shares earnings per share and revenue

On Aug 06, 2026, DFTX reported earnings of -1.44 USD per share (EPS) for Q2 26, missing the estimate of -0.55 USD, resulting in a -158.25% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -0.56 USD, with revenue projected to reach -- USD, implying an decrease of -61.11% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Champions Oncology, Inc.

Report Date

Sep 10, 2026 For Q1 27

Estimate

-$0.01

Actual

-$0.03

Surprise

-194.12%

PharmaCyte Biotech, Inc. Common Stock

Report Date

Sep 14, 2026 For Q1 27

Estimate

Actual

-$0.54

Surprise

FAQ

What were Definium Therapeutics, Inc. Common Shares's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Definium Therapeutics, Inc. Common Shares reported EPS of -$1.44, missing estimates by -158.25%, and revenue of $0.00, 0% as expectations.

How did the market react to Definium Therapeutics, Inc. Common Shares's Q2 2026 earnings?

The stock price moved -- 0%, changed from $46.14 before the earnings release to $46.14 the day after.

When is Definium Therapeutics, Inc. Common Shares expected to report next?

The next earning report is scheduled for Nov 04, 2026.

What are the forecasts for Definium Therapeutics, Inc. Common Shares's next earnings report?

Based on -- analysts, Definium Therapeutics, Inc. Common Shares is expected to report EPS of -$0.56 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.